Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9131441rdf:typepubmed:Citationlld:pubmed
pubmed-article:9131441lifeskim:mentionsumls-concept:C0870134lld:lifeskim
pubmed-article:9131441lifeskim:mentionsumls-concept:C0038250lld:lifeskim
pubmed-article:9131441lifeskim:mentionsumls-concept:C0229664lld:lifeskim
pubmed-article:9131441lifeskim:mentionsumls-concept:C0449468lld:lifeskim
pubmed-article:9131441lifeskim:mentionsumls-concept:C0023416lld:lifeskim
pubmed-article:9131441lifeskim:mentionsumls-concept:C0680854lld:lifeskim
pubmed-article:9131441lifeskim:mentionsumls-concept:C1515895lld:lifeskim
pubmed-article:9131441pubmed:issue2lld:pubmed
pubmed-article:9131441pubmed:dateCreated1997-7-1lld:pubmed
pubmed-article:9131441pubmed:abstractTextWe have investigated the efficiency and safety of large volume leukapheresis (LVL) for the collection of granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood progenitor cells (PBPCs) from healthy donors. In six apheresis sessions in four healthy individuals on a COBE-BCT Spectra cell separator (median processed volume 3.5 X total blood volume, TBV, range 3.3-4.4 X TBV), harvested cells were collected sequentially into three single bags. The collection bags were changed after processing 33%, 66%, and 100% of the prospective apheresis volume, allowing analysis of PBPCs collected at different periods during one harvest. Mononuclear cells (MNCs), CD34+ cells, CD34+ subsets, and lymphocyte subsets were determined in each bag. Substantially more PBPCs were harvested than were in the circulation before G-CSF administration preceding LVL (median 171%, range 69-267%), reflecting progenitor release during the procedure. In donors 1 and 3, the CD34+ cell yields decreased in the third bag to 53% and 42% of that collected in the first bag, whereas the progenitor cell yields in donors 2 and 4 were stable or rose during the procedure, achieving in the third bag 157% and 105% of the number of CD34+ cells collected in the first bag. Minor changes were found in the subsets of CD34+ cells, lymphocytes, and monocytes collected at different periods during a single harvest. LVL was well tolerated. Reversible thombocytopenia developed in all cases. No late effects attributable to LVL or G-CSF were found in the 4 donors and 16 other healthy individuals who have undergone LVL in our institution. We conclude that LVL is safe and maximizes PBPC yields for allogeneic transplantation.lld:pubmed
pubmed-article:9131441pubmed:languageenglld:pubmed
pubmed-article:9131441pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9131441pubmed:citationSubsetIMlld:pubmed
pubmed-article:9131441pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9131441pubmed:statusMEDLINElld:pubmed
pubmed-article:9131441pubmed:monthAprlld:pubmed
pubmed-article:9131441pubmed:issn1061-6128lld:pubmed
pubmed-article:9131441pubmed:authorpubmed-author:FischerJJlld:pubmed
pubmed-article:9131441pubmed:authorpubmed-author:WernetPPlld:pubmed
pubmed-article:9131441pubmed:authorpubmed-author:AulCClld:pubmed
pubmed-article:9131441pubmed:authorpubmed-author:HeyllAAlld:pubmed
pubmed-article:9131441pubmed:authorpubmed-author:SoehngenDDlld:pubmed
pubmed-article:9131441pubmed:authorpubmed-author:KobbeGGlld:pubmed
pubmed-article:9131441pubmed:authorpubmed-author:ThieleK PKPlld:pubmed
pubmed-article:9131441pubmed:issnTypePrintlld:pubmed
pubmed-article:9131441pubmed:volume6lld:pubmed
pubmed-article:9131441pubmed:ownerNLMlld:pubmed
pubmed-article:9131441pubmed:authorsCompleteYlld:pubmed
pubmed-article:9131441pubmed:pagination125-31lld:pubmed
pubmed-article:9131441pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:9131441pubmed:meshHeadingpubmed-meshheading:9131441-...lld:pubmed
pubmed-article:9131441pubmed:meshHeadingpubmed-meshheading:9131441-...lld:pubmed
pubmed-article:9131441pubmed:meshHeadingpubmed-meshheading:9131441-...lld:pubmed
pubmed-article:9131441pubmed:meshHeadingpubmed-meshheading:9131441-...lld:pubmed
pubmed-article:9131441pubmed:meshHeadingpubmed-meshheading:9131441-...lld:pubmed
pubmed-article:9131441pubmed:meshHeadingpubmed-meshheading:9131441-...lld:pubmed
pubmed-article:9131441pubmed:meshHeadingpubmed-meshheading:9131441-...lld:pubmed
pubmed-article:9131441pubmed:meshHeadingpubmed-meshheading:9131441-...lld:pubmed
pubmed-article:9131441pubmed:meshHeadingpubmed-meshheading:9131441-...lld:pubmed
pubmed-article:9131441pubmed:meshHeadingpubmed-meshheading:9131441-...lld:pubmed
pubmed-article:9131441pubmed:meshHeadingpubmed-meshheading:9131441-...lld:pubmed
pubmed-article:9131441pubmed:meshHeadingpubmed-meshheading:9131441-...lld:pubmed
pubmed-article:9131441pubmed:meshHeadingpubmed-meshheading:9131441-...lld:pubmed
pubmed-article:9131441pubmed:year1997lld:pubmed
pubmed-article:9131441pubmed:articleTitleLarge volume leukapheresis maximizes the progenitor cell yield for allogeneic peripheral blood progenitor donation.lld:pubmed
pubmed-article:9131441pubmed:affiliationDepartment of Hematology, Heinrich Heine University Düsseldorf, Germany.lld:pubmed
pubmed-article:9131441pubmed:publicationTypeJournal Articlelld:pubmed